MX2022014618A - Protocolo mejorado para tratamiento de nefritis lupica. - Google Patents

Protocolo mejorado para tratamiento de nefritis lupica.

Info

Publication number
MX2022014618A
MX2022014618A MX2022014618A MX2022014618A MX2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A MX 2022014618 A MX2022014618 A MX 2022014618A
Authority
MX
Mexico
Prior art keywords
treatment
lupus nephritis
improved protocol
protocol
improved
Prior art date
Application number
MX2022014618A
Other languages
English (en)
Inventor
Neil Solomons
Robert B Huizinga
Original Assignee
Aurinia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64095925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022014618(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aurinia Pharmaceuticals Inc filed Critical Aurinia Pharmaceuticals Inc
Publication of MX2022014618A publication Critical patent/MX2022014618A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Al emplear un régimen de dosificación farmacodinámico, la efectividad de un protocolo para tratamiento de una enfermedad renal proteinúrica con voclosporina se puede maximizar mientras que se minimizan los efectos secundarios indeseables.
MX2022014618A 2017-05-12 2019-11-08 Protocolo mejorado para tratamiento de nefritis lupica. MX2022014618A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505734P 2017-05-12 2017-05-12
US201762541612P 2017-08-04 2017-08-04
US15/835,219 US10286036B2 (en) 2017-05-12 2017-12-07 Protocol for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
MX2022014618A true MX2022014618A (es) 2023-01-30

Family

ID=64095925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014618A MX2022014618A (es) 2017-05-12 2019-11-08 Protocolo mejorado para tratamiento de nefritis lupica.

Country Status (23)

Country Link
US (1) US10286036B2 (es)
EP (2) EP4257138A3 (es)
JP (3) JP7050904B2 (es)
KR (1) KR20200007884A (es)
CN (1) CN111163794A (es)
AU (2) AU2018266850B2 (es)
BR (1) BR112019023766A2 (es)
CA (1) CA3063040A1 (es)
CL (1) CL2019003249A1 (es)
DK (1) DK3634463T3 (es)
ES (1) ES2965454T3 (es)
FI (1) FI3634463T3 (es)
HR (1) HRP20231469T1 (es)
HU (1) HUE064984T2 (es)
IL (2) IL270552B1 (es)
LT (1) LT3634463T (es)
MX (1) MX2022014618A (es)
PL (1) PL3634463T3 (es)
PT (1) PT3634463T (es)
RS (1) RS64959B1 (es)
SI (1) SI3634463T1 (es)
WO (1) WO2018207026A2 (es)
ZA (1) ZA201907460B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
KR100982466B1 (ko) 2001-10-19 2010-09-16 이소테크니카 인코포레이티드 시클로스포린 유사체의 합성
AR036852A1 (es) 2001-10-19 2004-10-06 Isotechnika Inc Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion
JP2005511538A (ja) * 2001-10-19 2005-04-28 アイソテクニカ インコーポレーテッド シクロスポリン類似体混合物及びそれらの免疫調節剤としての使用
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
CA2603970A1 (en) 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
US8628930B2 (en) * 2009-04-27 2014-01-14 Niigata University Use of megalin in urine as marker for detecting renal disorder
EP2531097B1 (en) 2010-02-02 2020-05-06 Accumen Inc. Methods and devices for reducing transfusions during or after surgery and for improving quality of life and function in chronic disease
CN103974701A (zh) * 2011-10-12 2014-08-06 思佰益药业股份有限公司 慢性肾脏病的改善、预防剂

Also Published As

Publication number Publication date
IL270552A (en) 2020-01-30
FI3634463T3 (fi) 2023-11-16
LT3634463T (lt) 2024-01-10
RU2019140834A (ru) 2021-06-15
AU2024202977A1 (en) 2024-05-23
DK3634463T3 (da) 2023-11-27
JP2023113884A (ja) 2023-08-16
BR112019023766A2 (pt) 2020-05-26
WO2018207026A3 (en) 2019-02-07
HRP20231469T1 (hr) 2024-03-01
PL3634463T3 (pl) 2024-03-04
US20180325995A1 (en) 2018-11-15
EP4257138A2 (en) 2023-10-11
EP3634463A2 (en) 2020-04-15
AU2018266850B2 (en) 2024-02-08
CA3063040A1 (en) 2018-11-15
SI3634463T1 (sl) 2024-04-30
EP3634463B9 (en) 2024-01-10
ES2965454T3 (es) 2024-04-15
JP2022095754A (ja) 2022-06-28
ZA201907460B (en) 2020-11-25
CN111163794A (zh) 2020-05-15
JP7295305B2 (ja) 2023-06-20
AU2018266850A1 (en) 2020-01-02
EP3634463A4 (en) 2021-03-17
HUE064984T2 (hu) 2024-04-28
RS64959B1 (sr) 2024-01-31
US10286036B2 (en) 2019-05-14
CL2019003249A1 (es) 2020-07-10
IL310731A (en) 2024-04-01
RU2019140834A3 (es) 2021-08-25
EP3634463B1 (en) 2023-09-27
JP2020519695A (ja) 2020-07-02
JP7050904B2 (ja) 2022-04-08
AU2018266850A2 (en) 2020-02-06
EP4257138A3 (en) 2024-01-03
PT3634463T (pt) 2023-12-05
IL270552B1 (en) 2024-03-01
WO2018207026A2 (en) 2018-11-15
KR20200007884A (ko) 2020-01-22

Similar Documents

Publication Publication Date Title
PL3577110T3 (pl) Związki podstawione 8-oksetan-3-ylo-3,8-diazabicyklo[3.2.1]oktan-3-ylem jako inhibitory hiv
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2019005076A (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.
MX2018006148A (es) Inhibidores de cxcr2.
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX2015010680A (es) Combinaciones que comprenden compuestos maba y corticosteroides.
PH12017502237A1 (en) Nuclear receptor modulators
MX2020009413A (es) Celulas t car-cd30 para el tratamiento de tumores cd30+.
TN2019000210A1 (en) Antitumoral compounds
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
MX2023006416A (es) Anticuerpos, usos y metodos.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
TN2018000326A1 (en) Granule formulation for oral administration.
MX2022014618A (es) Protocolo mejorado para tratamiento de nefritis lupica.
TWD196718S (zh) 夾鉗
MX2021000797A (es) Anticuerpos agonistas de cd226.
PH12018500999A1 (en) Sodium channel blocker
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
IN2014CH00304A (es)
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
Глущенко A small country
MY181479A (en) An anti-fungal composition derived from syzygium leucoxylon
Lieussou Dix mois autour du monde
TWD201430S (zh) 鞋底